European Penny Stocks To Watch In March 2025

The European market has recently experienced a mix of gains and losses, with the pan-European STOXX Europe 600 Index snapping a streak of ten consecutive weeks of growth amid uncertainties surrounding U.S. trade policies. Despite these challenges, the potential for increased spending on defense and infrastructure by Germany and the EU offers some optimism for investors. Although "penny stocks" might seem like an outdated term, they still represent an intriguing investment area, particularly when these smaller or newer companies are backed by strong financials. In this article, we highlight three penny stocks that combine balance sheet strength with promising potential for growth in today's market landscape.

Top 10 Penny Stocks In Europe

Name	Share Price	Market Cap	Financial Health Rating
Angler Gaming (NGM:ANGL)	SEK3.85	SEK288.69M	★★★★★★
Transferator (NGM:TRAN A)	SEK2.22	SEK211.54M	★★★★★★
Netgem (ENXTPA:ALNTG)	€0.99	€33.15M	★★★★★★
Hifab Group (OM:HIFA B)	SEK3.84	SEK233.62M	★★★★★★
High (ENXTPA:HCO)	€2.67	€52.44M	★★★★★★
Deceuninck (ENXTBR:DECB)	€2.23	€308.62M	★★★★★★
I.M.D. International Medical Devices (BIT:IMD)	€1.37	€23.73M	★★★★★☆
Bredband2 i Skandinavien (OM:BRE2)	SEK2.02	SEK1.93B	★★★★☆☆
TTS (Transport Trade Services) (BVB:TTS)	RON4.765	RON858.82M	★★★★★★
IMS (WSE:IMS)	PLN3.61	PLN122.36M	★★★★☆☆

Click here to see the full list of 435 stocks from our European Penny Stocks screener.

Let's explore several standout options from the results in the screener.

Aelis Farma (ENXTPA:AELIS)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Aelis Farma SA is a clinical-stage biotechnology company dedicated to discovering and developing drug candidates for central nervous system disorders, with a market cap of €23.15 million.

Operations: The company's revenue is solely derived from its Research and Development of Pharmaceutical Products segment, amounting to €10.78 million.

Market Cap: €23.15M

Aelis Farma, with a market cap of €23.15 million, operates in the biotechnology sector focusing on central nervous system disorders. Despite being pre-revenue and currently unprofitable with a negative return on equity of -70.68%, the company is trading at good value compared to peers and industry standards. The management team is experienced, averaging 3.2 years in tenure, while Aelis's short-term assets of €18.8 million cover both its short- and long-term liabilities comfortably. The company's share price has been highly volatile recently; however, it maintains more cash than total debt and has not diluted shareholders meaningfully over the past year.

• Click to explore a detailed breakdown of our findings in Aelis Farma's financial health report.
• Explore Aelis Farma's analyst forecasts in our growth report.

Mister Spex (XTRA:MRX)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Mister Spex SE is a company that provides and markets eyewear products in Germany and internationally, with a market cap of €52.13 million.

Operations: The company generates revenue from its Online Retailers segment, amounting to €226.51 million.

Market Cap: €52.13M

Mister Spex SE, with a market cap of €52.13 million, is unprofitable and has seen losses increase by 29.5% annually over the past five years. Despite this, the company benefits from a strong financial position with short-term assets (€131.1M) exceeding both short- and long-term liabilities (€43.2M and €67.4M respectively) and more cash than total debt. The management team is relatively new (1.2 years average tenure), while the board of directors is experienced (3.8 years average tenure). Although share price volatility remains high, shareholders have not been meaningfully diluted recently, offering some stability in ownership structure.

• Click here to discover the nuances of Mister Spex with our detailed analytical financial health report.
• Evaluate Mister Spex's prospects by accessing our earnings growth report.

Viscom (XTRA:V6C)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Viscom SE develops, manufactures, and sells inspection systems for industrial production applications across Europe, the Americas, and Asia with a market cap of €30.12 million.

Operations: The company's revenue is primarily derived from Europe (excluding Germany) at €68.12 million, followed by Germany at €33.36 million, Asia at €26.21 million, and the Americas at €14.3 million.

Market Cap: €30.12M

Viscom SE, with a market cap of €30.12 million, is currently unprofitable with a negative return on equity of -4.73%. Despite this, the company has a seasoned management team averaging 13.8 years in tenure and stable weekly volatility at 6%. Short-term assets (€70.9M) comfortably cover both short- and long-term liabilities (€37.1M and €9.5M respectively), while operating cash flow adequately covers debt (118.7%). Although trading at nearly its estimated fair value, Viscom's debt-to-equity ratio has increased over five years to 36.9%, indicating rising leverage but remains within satisfactory levels at 29.7% net debt to equity ratio.

• Dive into the specifics of Viscom here with our thorough balance sheet health report.
• Gain insights into Viscom's outlook and expected performance with our report on the company's earnings estimates.

Taking Advantage

• Dive into all 435 of the European Penny Stocks we have identified here.
• Shareholder in one or more of these companies? Ensure you're never caught off-guard by adding your portfolio in Simply Wall St for timely alerts on significant stock developments.
• Maximize your investment potential with Simply Wall St, the comprehensive app that offers global market insights for free.

Seeking Other Investments?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Jump on the AI train with fast growing tech companies forging a new era of innovation.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com